IPO Performance Review: Cerebras shares have seen notable volatility since the May debut, with the price pulling back from opening levels as investors digest the implications of aggressive AI hardware valuations. Market participants highlight the rapid growth in inference demand as a key driver behind the company's positioning.
Analyst Ratings Impact: A wave of brokerage initiations following the quiet period established a range of price targets, prompting discussions on whether current trading levels align with expected revenue trajectories. Observers note the upcoming earnings release as a critical near-term checkpoint.
Fund Activity Buzz: High-profile institutional purchases have fueled conversations around the sustainability of AI infrastructure momentum, even as some express caution over post-IPO price action relative to initial hype.
Note: This discussion summary was generated from an AI condensation of post data.
Cerebras Analyst Ratings
Wall Street analysts have issued reports on $CBRS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 06/08/2026
To track analyst ratings and price targets for Cerebras, check out Quiver Quantitative's $CBRS forecast page.
Cerebras Price Targets
Multiple analysts have issued price targets for $CBRS recently. We have seen 10 analysts offer price targets for $CBRS in the last 6 months, with a median target of $300.0.
Here are some recent targets:
- Richard Shannon from Craig-Hallum set a target price of $325.0 on 06/09/2026
- N. Quinn Bolton from Needham set a target price of $300.0 on 06/08/2026
- Atif Malik from Citigroup set a target price of $340.0 on 06/08/2026
- Tom O'Malley from Barclays set a target price of $280.0 on 06/08/2026
- Matt Bryson from Wedbush set a target price of $270.0 on 06/08/2026
- Kevin Cassidy from Rosenblatt set a target price of $300.0 on 06/08/2026
- Joshua Buchalter from TD Cowen set a target price of $275.0 on 06/08/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
